Models of Cancer Therapies Group

Home Tag

Copia de Copia de Banner web VHIO (2)

Laura Soucek receives an ERC Advanced Grant to maximize the clinical and preclinical use of the first viable MYC inhibitor

Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program, and Head of our Models of Cancer Therapies…

Copia de Copia de Banner web VHIO

VHIO spin-off Peptomyc awarded as the most innovative company of the year by El Periódico de Catalunya

Peptomyc, the VHIO and ICREA spin-off co-founded and directed by Dr. Laura Soucek, ICREA professor and director of the VHIO…

Banner web VHIO (1300 × 600 px) (36)

The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first MYC oncogene inhibitor

The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…

Banner web VHIO (1300 × 600 px) (36)

VHIO’s spin-off Peptomyc is awarded €5 million from EIC Accelerator Program to conduct a Phase 1b clinical trial in patients with pancreatic cancer

The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…

vhio-compo-fotos-1550x900

MYC inhibition in melanoma: preclinical promise and the unveiling of a prognostic gene signature

Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…